title: [Transplantations of allogenic and autologous hemopoietic stem cells in acute leukemia (results of 20-year experience)].
abstract: OBJECTIVE
  To analyse results of transplantation of allogenic and autologous hemopoietic stem cells (allo-THSC and auto-THSC) with myeloablation preconditioning in patients with acute leukemia (AL) performed in 1987-2006.
  
  
  METHODS
  A total of 71 allogenic and 45 autologous THSC were performed in 116 patients with different AL variants. Conditioning in all allo-THSC included busulfan (16 mg/kg) and cyclophosphamide (120 mg/kg). This regimen was used in 29 recipients of auto-HSC. Cyclophosphamide in a dose 120 mg/kg and total radiation of the body in a dose 12 Gy were given to 16 recipients. Overall, relapse-free and event-free survival of patients after THSC were analysed as well as early (first 100 days) and overall lethality. Auto-THSC in 15 patients was for the first time followed by immunomodulating therapy aimed at prevention of AL relapses: in acute myeloid leukemia ATRA in combination with alpha-interferon, in acute lymphoblastic leukemia (ALL)--ronkoleukin, interleukin-2 preparation.
  
  
  RESULTS
  Overall survival of AL patients after allo-THSC for the observation period increased from 31 to 58%, early lethality fell from 44 to 4%. Results of allo-THSC conducted in the first complete remission were much better than in patients with other AL stages at the time of THSC. After auto-THSC 5-year survival rose from 22 to 60% while early lethality reduced from 33 to 4%. Administration of immunomodulating therapy after auto-THSC increases 5-year survival from 35 to 80%.
  
  
  CONCLUSIONS
  Outcomes of THSC in AL has improved for the last 20 years. Outcomes of allo-THSC performed in the first complete remission are much higher. Immunomodulating therapy after auto-THSC promoted better results.
authors.forename: V G
authors.initials: VG
authors.lastname: Savchenko
authors.forename: L S
authors.initials: LS
authors.lastname: Liubimova
authors.forename: E N
authors.initials: EN
authors.lastname: Parovichnikova
authors.forename: L P
authors.initials: LP
authors.lastname: Mendeleeva
authors.forename: K S
authors.initials: KS
authors.lastname: Mamotiuk
authors.forename: I A
authors.initials: IA
authors.lastname: Demidova
authors.forename: E O
authors.initials: EO
authors.lastname: Gribanova
authors.forename: I V
authors.initials: IV
authors.lastname: Gal'tseva
authors.forename: O S
authors.initials: OS
authors.lastname: Pokrovskaia
authors.forename: L A
authors.initials: LA
authors.lastname: Kuz'mina
authors.forename: E I
authors.initials: EI
authors.lastname: Zhelnova
authors.forename: G A
authors.initials: GA
authors.lastname: Kliasova
authors.forename: E N
authors.initials: EN
authors.lastname: Glasko
authors.forename: I B
authors.initials: IB
authors.lastname: Kaplanskaia
authors.forename: L P
authors.initials: LP
authors.lastname: Poreshina
authors.forename: R M
authors.initials: RM
authors.lastname: Kut'ina
authors.forename: A P
authors.initials: AP
authors.lastname: Shpakova
authors.forename: E M
authors.initials: EM
authors.lastname: Shtareva
authors.forename: S V
authors.initials: SV
authors.lastname: Varlamova
authors.forename: N N
authors.initials: NN
authors.lastname: Kalinin
mesh_terms: D000208:Acute Disease; D000293:Adolescent; D000328:Adult; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007167:Immunotherapy; D007951:Leukemia, Myeloid / Q000401:mortality* / Q000601:surgery* / Q000628:therapy; D008297:Male; D016019:Survival Analysis; D014182:Transplantation, Autologous; D014184:Transplantation, Homologous; D016896:Treatment Outcome